National Cancer Institute (NCI): Carcinoma, Renal Cell trials

The registry lists 118 Carcinoma, Renal Cell studies with National Cancer Institute (NCI) as lead sponsor. 9 are open to participants now and 50 have results posted.

Phase 1 43Phase 2 76Phase 3 7No phase 6(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00082914Phase 2
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerCompletedNCT00060307Phase 2
• Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell CancerCompletedNCT00059813Phase 2
• Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney CancerCompletedNCT00032188Phase 2
• Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug ResistanceCompletedNCT00026663
• Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00020540Phase 1
• Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)CompletedNCT00019955Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney CancerCompletedNCT00019539Phase 2
• flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell CancerCompletedNCT00019396Phase 2
• Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00018941Phase 3
• SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous TreatmentTerminatedNCT00009919Phase 2
• Carboxyamidotriazole in Treating Patients With Metastatic Kidney CancerCompletedNCT00006486Phase 2
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant MelanomaCompletedNCT00004244Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Bryostatin 1 in Treating Patients With Metastatic Kidney CancerCompletedNCT00003968Phase 2
• Lymphocyte Therapy in Treating Patients With Kidney CancerStatus unknownNCT00002589Phase 2
• A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic CancerCompletedNCT00001683Phase 1
• A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833CompletedNCT00001383Phase 1